The rise and fall and rise again of 23andMe

Nature. 2017 Oct 11;550(7675):174-177. doi: 10.1038/550174a.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Benzylisoquinolines / therapeutic use
  • Biosensing Techniques
  • Bloom Syndrome / diagnosis
  • Bloom Syndrome / genetics
  • Cardiovascular Diseases / drug therapy
  • Disclosure / ethics
  • Drug Discovery / methods*
  • False Positive Reactions
  • Gaucher Disease / drug therapy
  • Genes, BRCA1
  • Genes, BRCA2
  • Genetic Predisposition to Disease*
  • Genetic Testing / economics
  • Genetic Testing / legislation & jurisprudence*
  • Genome-Wide Association Study
  • Heredity
  • Humans
  • Iceland
  • Immune System Diseases / drug therapy
  • Information Dissemination
  • Neoplasms / diagnosis
  • Neoplasms / genetics
  • Parkinson Disease / drug therapy
  • Pharmacogenetics
  • Predictive Value of Tests
  • Reproducibility of Results
  • Self Report
  • Skin Diseases / drug therapy
  • Translational Research, Biomedical
  • United States
  • United States Food and Drug Administration / legislation & jurisprudence*

Substances

  • Antibodies, Monoclonal
  • Benzylisoquinolines
  • romosozumab
  • fangchinoline